Evaluating the Future Treatment Landscape for Lipoprotein(a) management and the Potential of Pelacarsen (Novartis), Olpasiran (Amgen), and Lepodisiran (Eli Lilly)

Executed on:Apr 14, 2026 3:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Western UniversityDistinguished Professor of Medicine and Biochemistry at Western University in London, Ontario, Canada.
Manages >2500 patients in his lipid clinic, 25 with FCS.
Among the first in the world to use five medications that are now routinely prescribed to treat dyslipidemia or diabetes, has co-authored many clinical practice guidelines for cholesterol, blood pressure and diabete, and has published >900 papers.

Interview Goal

This call will discuss the current treatment landscape for Lipoprotein(a) and the potential of Pelacarsen from Novartis, OLPASIRAN from Amgen, and lepodisiran from Eli Lilly.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.